Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
This article was originally published in The Pink Sheet Daily
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.
You may also be interested in...
The rheumatoid arthritis agent is expected to be available by the end of February.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.